Description
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:
adult patients with unresectable or metastatic HER2-positive breast cancer
adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC)
adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
Note: Enhertu (Trastuzumab Deruxtecan) is an FDA approved medicine.
Reviews
There are no reviews yet.